NASDAQ NMS - GLOBAL MARKET · OTLK
+4.88% · +$0.0475 · Vol 4.6M
Market closed · last close 4:00 PM ET · price as of 19:55:46 ET
Outlook Therapeutics Inc

Outlook Therapeutics Inc

Biotechnology
$1.02
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
OTLK
Outlook Therapeutics Inc
Fri Aug 7 · market closed · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 7 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is OTLK moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading OTLK catalysts
About Outlook Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2016
Employees
17
Country
US

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.9861
Day high
$1.04
Day low
$0.9500
Previous close
$0.9725
52W high
$2.97
-65.66% from high
52W low
$0.1981
30% of range
Market cap
$181.9M
EPS
$-2.4800
Beta
0.50
Shares out
187M
Volume
4.6M
0.37× rel vol
Avg volume
12.4M
VWAP
$1.00
Price history computed in-house
1W
+4.44%
1M
-39.29%
3M
+360.91%
1Y
-46.32%
YTD
-35.44%
SMA 50 $1.26 · below
SMA 200 $0.9239 · above
52W position 30%

OTLK overview

Veridion Score
59
4 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around OTLK.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading OTLK Form 4 filings
Public disclosures

Congress activity in OTLK

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for OTLK in the cached public ledger.

Federal contracts

OTLK contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for OTLK in this window.
Lobbying spend

OTLK lobbying filings, year to date.

Registered lobbying filings matched to Outlook Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for OTLK in this window.
Loading news for OTLK
Analyst ratings
Sovereign unlock shows live analyst consensus for OTLK.
Options
Sovereign unlock shows live options positioning for OTLK.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.